Neuropathix_Logo_wTag.png
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
06. Mai 2021 09:00 ET | Neuropathix, Inc.
DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the...
Neuropathix_Logo_wTag.png
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
25. Januar 2021 09:00 ET | Neuropathix, Inc.
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today...
Kannalife_logo_w-Tag.png
Kannalife Announces Completion of Name Change, Ticker Symbol Change
16. Januar 2019 09:00 ET | Kannalife, Inc.
DOYLESTOWN, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce that the Company’s name change...
Kannalife Sciences F
Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions Corp.
01. August 2018 08:00 ET | Kannalife Sciences, Inc.
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange...
Medical Marijuana Inc Primary
Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc.’s New Cannabis-Derived Compound KLS-13019 Covered by Reuters, Kannalife Explores IPO This Year
26. Februar 2016 09:00 ET | Medical Marijuana Inc
SAN DIEGO, Feb. 26, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce that the Company’s portfolio investment company, Kannalife Sciences, Inc. (“Kannalife”),...
Medical Marijuana Inc Primary
Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy
18. Februar 2016 09:00 ET | Medical Marijuana Inc
SAN DIEGO, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce that the Company’s portfolio investment company, Kannalife Sciences, Inc. (“Kannalife”),...
Neuropathix_Logo_wTag.png
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
16. Februar 2016 11:15 ET | Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...
Neuropathix_Logo_wTag.png
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
16. Februar 2016 11:15 ET | Kannalife, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of...